Truist upgrades Evolent Health to Buy with $6 price target

Truist Securities raised its rating on Evolent Health (EVH) from Hold to Buy and set a $6.00 price target. The firm highlighted the stock's recent 30% weekly decline as an entry point and cited improved visibility into 2027 earnings. Truist now expects the midpoint of EVH's 2027 adjusted EBITDA guidance to be at least $150 million. The upgrade follows EVH's third‑quarter results, which showed revenue of $725.4 million and adjusted EBITDA of $34.3 million.

Truist’s $6 target represents a 74.9% upside from the $3.43 close on Nov 19, which may draw buying interest. The higher 2027 EBITDA outlook could support a re‑rating of the stock by other analysts.

  • 1Truist upgraded EVH to Buy from Hold and set a $6.00 price target.
  • 2EVH shares were trading at $3.43, down 30% week‑to‑date.
  • 3Truist expects the midpoint of EVH's 2027 adjusted EBITDA guidance to be at least $150 million.
  • 4EVH reported third‑quarter revenue of $725.4 million.
  • 5Adjusted EBITDA for the quarter was $34.3 million.
  • 6Truist’s $6 target implies a 74.9% upside from the Nov 19 close of $3.43.

Sources